Emerging pharmaceutical therapies for osteoarthritis.
Journal
Nature reviews. Rheumatology
ISSN: 1759-4804
Titre abrégé: Nat Rev Rheumatol
Pays: United States
ID NLM: 101500080
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
accepted:
23
09
2020
pubmed:
31
10
2020
medline:
17
2
2021
entrez:
30
10
2020
Statut:
ppublish
Résumé
The prevalence of osteoarthritis (OA) and the burden associated with the disease are steadily increasing worldwide, representing a major public health challenge for the coming decades. The lack of specific treatments for OA has led to it being recognized as a serious disease that has an unmet medical need. Advances in the understanding of OA pathophysiology have enabled the identification of a variety of potential therapeutic targets involved in the structural progression of OA, some of which are promising and under clinical investigation in randomized controlled trials. Emerging therapies include those targeting matrix-degrading proteases or senescent chondrocytes, promoting cartilage repair or limiting bone remodelling, local low-grade inflammation or Wnt signalling. In addition to these potentially disease-modifying OA drugs (DMOADs), several targets are being explored for the treatment of OA-related pain, such as nerve growth factor inhibitors. The results of these studies are expected to considerably reshape the landscape of OA management over the next few years. This Review describes the pathophysiological processes targeted by emerging therapies for OA, along with relevant clinical data and discussion of the main challenges for the further development of these therapies, to provide context for the latest advances in the field of pharmaceutical therapies for OA.
Identifiants
pubmed: 33122845
doi: 10.1038/s41584-020-00518-6
pii: 10.1038/s41584-020-00518-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
673-688Références
Hunter, D. J. & Bierma-Zeinstra, S. Osteoarthritis. Lancet 393, 1745–1759 (2019).
pubmed: 31034380
Wallace, I. J. et al. Knee osteoarthritis has doubled in prevalence since the mid-20th century. Proc. Natl Acad. Sci. USA 114, 9332–9336 (2017).
pubmed: 28808025
Hunter, D. J., Schofield, D. & Callander, E. The individual and socioeconomic impact of osteoarthritis. Nat. Rev. Rheumatol. 10, 437–441 (2014).
pubmed: 24662640
Safiri, S. et al. Global, regional and national burden of osteoarthritis 1990–2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann. Rheum. Dis. 79, 819–828 (2020).
pubmed: 32398285
Bannuru, R. R. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 27, 1578–1589 (2019).
pubmed: 31278997
Gregori, D. et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA 320, 2564–2579 (2018).
pubmed: 30575881
pmcid: 6583519
McAlindon, T. E. et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA 317, 1967–1975 (2017).
pubmed: 28510679
pmcid: 5815012
Kolasinski, S. L. et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 72, 220–233 (2020).
pubmed: 31908163
Leopoldino, A. O. et al. Paracetamol versus placebo for knee and hip osteoarthritis. Cochrane Database Syst. Rev. 2, CD013273 (2019).
pubmed: 30801133
Roberts, E. et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann. Rheum. Dis. 75, 552–559 (2016).
pubmed: 25732175
da Costa, B. R. et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst. Rev. 9, CD003115 (2014).
Fuggle, N. et al. Safety of opioids in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging 36, 129–143 (2019).
pubmed: 31073926
pmcid: 6509215
Krebs, E. E. et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA 319, 872–882 (2018).
pubmed: 29509867
pmcid: 5885909
Zeng, C. et al. Association of tramadol with all-cause mortality among patients with osteoarthritis. JAMA 321, 969–982 (2019).
pubmed: 30860559
pmcid: 6439672
Bannuru, R. R. et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann. Intern. Med. 162, 46–54 (2015).
pubmed: 25560713
da Costa, B. R. et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 390, e21–e33 (2017).
pubmed: 28699595
Bally, M. et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 357, j1909 (2017).
pubmed: 28487435
pmcid: 5423546
Nissen, S. E. et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N. Engl. J. Med. 375, 2519–2529 (2016).
pubmed: 27959716
Trelle, S. et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342, c7086 (2011).
pubmed: 21224324
pmcid: 3019238
Atiquzzaman, M., Karim, M. E., Kopec, J., Wong, H. & Anis, A. H. Role of nonsteroidal antiinflammatory drugs in the association between osteoarthritis and cardiovascular diseases: a longitudinal study. Arthritis Rheumatol. 71, 1835–1843 (2019).
pubmed: 31389178
Jüni, P. et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst. Rev. 10, CD005328 (2015).
Zeng, C. et al. Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative. Osteoarthritis Cartilage 27, 855–862 (2019).
pubmed: 30703543
Rutjes, A. W. et al. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann. Intern. Med. 157, 180–191 (2012).
pubmed: 22868835
Honvo, G. et al. Safety of intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging 36, 101–127 (2019).
pubmed: 31073925
pmcid: 6509101
US Food and Drug Administration. Osteoarthritis: structural endpoints for the development of drugs (FDA, 2018).
Loeser, R. F., Goldring, S. R., Scanzello, C. R. & Goldring, M. B. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 64, 1697–1707 (2012).
pubmed: 22392533
pmcid: 3366018
Stampella, A., Monteagudo, S. & Lories, R. Wnt signaling as target for the treatment of osteoarthritis. Best Pract. Res. Clin. Rheumatol. 31, 721–729 (2017).
pubmed: 30509416
Conaghan, P. G., Cook, A. D., Hamilton, J. A. & Tak, P. P. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat. Rev. Rheumatol. 15, 355–363 (2019).
pubmed: 31068673
Styrkarsdottir, U. et al. Meta-analysis of Icelandic and UK data sets identifies missense variants in SMO, IL11, COL11A1 and 13 more new loci associated with osteoarthritis. Nat. Genet. 50, 1681–1687 (2018).
pubmed: 30374069
Tachmazidou, I. et al. Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data. Nat. Genet. 51, 230–236 (2019).
pubmed: 30664745
pmcid: 6400267
Zengini, E. et al. Genome-wide analyses using UK Biobank data provide insights into the genetic architecture of osteoarthritis. Nat. Genet. 50, 549–558 (2018).
pubmed: 29559693
pmcid: 5896734
Hochberg, M. C. et al. Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial. JAMA 322, 1360–1370 (2019).
pubmed: 31593273
pmcid: 6784851
Conaghan, P. G. et al. Disease-modifying effects of a novel cathepsin K inhibitor in osteoarthritis: a randomized, placebo-controlled study. Ann. Intern. Med. 172, 86–95 (2019).
pubmed: 31887743
Bedson, J. & Croft, P. R. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskelet. Disord. 9, 116 (2008).
pubmed: 18764949
pmcid: 2542996
Eckstein, F. et al. Comparison of radiographic joint space width and magnetic resonance imaging for prediction of knee replacement: a longitudinal case-control study from the Osteoarthritis Initiative. Eur. Radiol. 26, 1942–1951 (2016).
pubmed: 26376884
Troeberg, L. & Nagase, H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim. Biophys. Acta 1824, 133–145 (2012).
pubmed: 21777704
Glasson, S. S. et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434, 644–648 (2005).
pubmed: 15800624
Little, C. B. et al. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum. 60, 3723–3733 (2009).
pubmed: 19950295
pmcid: 2832925
Stanton, H. et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434, 648–652 (2005).
pubmed: 15800625
Neuhold, L. A. et al. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J. Clin. Invest. 107, 35–44 (2001).
pubmed: 11134178
pmcid: 198546
Krzeski, P. et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res. Ther. 9, R109 (2007).
pubmed: 17958901
pmcid: 2212568
Vandenbroucke, R. E. & Libert, C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat. Rev. Drug Discov. 13, 904–927 (2014).
pubmed: 25376097
Malfait, A. M. & Tortorella, M. D. The “elusive DMOAD”: aggrecanase inhibition from laboratory to clinic. Clin. Exp. Rheumatol. 37 (Suppl. 120), 130–134 (2019).
pubmed: 31621572
Clement-Lacroix, P. et al. ADAMTS-5 inhibition with the potent and highly selective inhibitor GLPG1972 results in strong disease-modifying OA drug effects in the rat meniscectomy model [abstract]. Osteoarthritis Cartilage 26, S26 (2018).
Clement-Lacroix, P. et al. GLPG1972: a potent, selective, orally available adamts-5 inhibitor for the treatment of OA [abstract]. Osteoarthritis Cartilage 25, S58–S59 (2017).
van der Aar, E. M. et al. ADAMTS-5 inhibitor GLPG1972, a potential new treatment in osteoarthritis, shows favorable safety, pharmacokinetics and pharmacodynamics in healthy subjects [abstract]. Osteoarthritis Cartilage 26, S310 (2018).
Lalande, A. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics in healthy male Japanese subjects of the ADAMTS-5 inhibitor S201086/GLPG1972, a potential new treatment in OA [abstract]. Arthritis Rheumatol. 71 (2019).
Siebuhr, A. et al. The anti-ADAMTS-5 nanobody®, M6495, protects against cartilage breakdown in cartilage and synovial joint tissue explant models [abstract]. Osteoarthritis Cartilage 26, S187 (2018).
Werkmann, D. et al. In vitro characterization of the ADAMTS-5 specific nanobody® M6495 [abstract]. Osteoarthritis Cartilage 26, S178 (2018).
Guehring, H. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of the anti-ADAMTS-5 Nanobody®, M6495, in healthy male subjects: a phase I, placebo-controlled, first-in-human study [abstract]. Arthritis Rheumatol. 71 (2019).
Jeon, O. H., David, N., Campisi, J. & Elisseeff, J. H. Senescent cells and osteoarthritis: a painful connection. J. Clin. Invest. 128, 1229–1237 (2018).
pubmed: 29608139
pmcid: 5873863
Loeser, R. F., Collins, J. A. & Diekman, B. O. Ageing and the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol. 12, 412–420 (2016).
pubmed: 27192932
pmcid: 4938009
Jeon, O. H. et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat. Med. 23, 775–781 (2017).
pubmed: 28436958
pmcid: 5785239
Hsu, B. et al. Safety, tolerability, pharmacokinetics, and clinical outcomes following single-dose IA administration of UBX0101, a senolytic MDM2/p53 interaction inhibitor, in patients with knee OA [abstract]. Arthritis Rheumatol. 71 (2019).
Yousefzadeh, M. J. et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36, 18–28 (2018).
pubmed: 30279143
pmcid: 6197652
Zheng, W. et al. Fisetin inhibits IL-1beta-induced inflammatory response in human osteoarthritis chondrocytes through activating SIRT1 and attenuates the progression of osteoarthritis in mice. Int. Immunopharmacol. 45, 135–147 (2017).
pubmed: 28213268
Ellsworth, J. L. et al. Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. Osteoarthritis Cartilage 10, 308–320 (2002).
pubmed: 11950254
Moore, E. E. et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage 13, 623–631 (2005).
pubmed: 15896984
Mori, Y. et al. Identification of fibroblast growth factor-18 as a molecule to protect adult articular cartilage by gene expression profiling. J. Biol. Chem. 289, 10192–10200 (2014).
pubmed: 24577103
pmcid: 3974988
Gigout, A. et al. Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix. Osteoarthritis Cartilage 25, 1858–1867 (2017).
pubmed: 28823647
Reker, D. et al. Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo. J. Transl. Med. 15, 250 (2017).
pubmed: 29233174
pmcid: 5727954
Lohmander, L. S. et al. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 66, 1820–1831 (2014).
pubmed: 24740822
Eckstein, F., Wirth, W., Guermazi, A., Maschek, S. & Aydemir, A. Brief report: intraarticular sprifermin not only increases cartilage thickness, but also reduces cartilage loss: location-independent post hoc analysis using magnetic resonance imaging. Arthritis Rheumatol. 67, 2916–2922 (2015).
pubmed: 26138203
pmcid: 5061102
Roemer, F. W. et al. Structural effects of sprifermin in knee osteoarthritis: a post-hoc analysis on cartilage and non-cartilaginous tissue alterations in a randomized controlled trial. BMC Musculoskelet. Disord. 17, 267 (2016).
pubmed: 27393009
pmcid: 4938999
Gühring, H. et al. OP0010 cartilage thickness modification with sprifermin in knee osteoarthritis patients translates into symptomatic improvement over placebo in patients at risk of further structural and symptomatic progression: post-hoc analysis of the phase II FORWARD trial. Ann. Rheum. Dis. 78, 70–71 (2019).
van der Kraan, P. M. The changing role of TGFbeta in healthy, ageing and osteoarthritic joints. Nat. Rev. Rheumatol. 13, 155–163 (2017).
pubmed: 28148919
Noh, M. J. et al. Pre-clinical studies of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 (TG-C). Cytotherapy 12, 384–393 (2010).
pubmed: 20370350
Ha, C. W., Noh, M. J., Choi, K. B. & Lee, K. H. Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients. Cytotherapy 14, 247–256 (2012).
pubmed: 22242865
pmcid: 3793276
Guermazi, A. et al. Structural effects of intra-articular TGF-β1 in moderate to advanced knee osteoarthritis: MRI-based assessment in a randomized controlled trial. BMC Musculoskelet. Disord. 18, 461 (2017).
pubmed: 29145839
pmcid: 5689208
Lee, B. et al. Results of a phase II study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-beta1. J. Knee Surg. 33, 167–172 (2019).
pubmed: 30609439
Kim, M. K. et al. A multicenter, double-blind, phase III clinical trial to evaluate the efficacy and safety of a cell and gene therapy in knee osteoarthritis patients. Hum. Gene Ther. Clin. Dev. 29, 48–59 (2018).
pubmed: 29641281
Harrell, C. R., Markovic, B. S., Fellabaum, C., Arsenijevic, A. & Volarevic, V. Mesenchymal stem cell-based therapy of osteoarthritis: current knowledge and future perspectives. Biomed. Pharmacother. 109, 2318–2326 (2019).
pubmed: 30551490
Xing, D. et al. Intra-articular injection of mesenchymal stem cells in treating knee osteoarthritis: a systematic review of animal studies. Osteoarthritis Cartilage 26, 445–461 (2018).
pubmed: 29427723
Emadedin, M. et al. Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Cytotherapy 20, 1238–1246 (2018).
pubmed: 30318332
Freitag, J. et al. Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial. Regen. Med. 14, 213–230 (2019).
pubmed: 30762487
Kim, S. H. et al. Intra-articular injection of mesenchymal stem cells for clinical outcomes and cartilage repair in osteoarthritis of the knee: a meta-analysis of randomized controlled trials. Arch. Orthop. Trauma. Surg. 139, 971–980 (2019).
pubmed: 30756165
Lee, W. S., Kim, H. J., Kim, K. I., Kim, G. B. & Jin, W. Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells for the treatment of knee osteoarthritis: a phase iib, randomized, placebo-controlled clinical trial. Stem Cell Transl. Med. 8, 504–511 (2019).
Pers, Y. M. et al. Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: a phase I dose-escalation trial. Stem Cell Transl. Med. 5, 847–856 (2016).
De Bari, C. & Roelofs, A. J. Stem cell-based therapeutic strategies for cartilage defects and osteoarthritis. Curr. Opin. Pharmacol. 40, 74–80 (2018).
pubmed: 29625333
Decker, R. S. et al. Cell origin, volume and arrangement are drivers of articular cartilage formation, morphogenesis and response to injury in mouse limbs. Dev. Biol. 426, 56–68 (2017).
pubmed: 28438606
pmcid: 6046638
Roelofs, A. J. et al. Joint morphogenetic cells in the adult mammalian synovium. Nat. Commun. 8, 15040 (2017).
pubmed: 28508891
pmcid: 5493527
ter Huurne, M. et al. Antiinflammatory and chondroprotective effects of intraarticular injection of adipose-derived stem cells in experimental osteoarthritis. Arthritis Rheum. 64, 3604–3613 (2012).
pubmed: 22961401
Goldring, S. R. & Goldring, M. B. Changes in the osteochondral unit during osteoarthritis: structure, function and cartilage-bone crosstalk. Nat. Rev. Rheumatol. 12, 632–644 (2016).
pubmed: 27652499
Zhen, G. et al. Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat. Med. 19, 704–712 (2013).
pubmed: 23685840
pmcid: 3676689
Funck-Brentano, T. et al. Dkk-1-mediated inhibition of Wnt signaling in bone ameliorates osteoarthritis in mice. Arthritis Rheumatol. 66, 3028–3039 (2014).
pubmed: 25080367
Fang, H. et al. Early changes of articular cartilage and subchondral bone in the DMM mouse model of osteoarthritis. Sci. Rep. 8, 2855 (2018).
pubmed: 29434267
pmcid: 5809364
Zhu, S. et al. Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. J. Clin. Invest. 129, 1076–1093 (2019).
pubmed: 30530994
pmcid: 6391093
Aso, K. et al. Associations of symptomatic knee osteoarthritis with histopathologic features in subchondral bone. Arthritis Rheumatol. 71, 916–924 (2019).
pubmed: 30663865
Nwosu, L. N. et al. Pain prediction by serum biomarkers of bone turnover in people with knee osteoarthritis: an observational study of TRAcP5b and cathepsin K in OA. Osteoarthritis Cartilage 25, 858–865 (2017).
pubmed: 28087412
Dearmin, M. G., Trumble, T. N., Garcia, A., Chambers, J. N. & Budsberg, S. C. Chondroprotective effects of zoledronic acid on articular cartilage in dogs with experimentally induced osteoarthritis. Am. J. Vet. Res. 75, 329–337 (2014).
pubmed: 24669915
Hayami, T. et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum. 50, 1193–1206 (2004).
pubmed: 15077302
Khorasani, M. S. et al. Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice. Arthritis Res. Ther. 17, 30 (2015).
pubmed: 25888819
pmcid: 4355375
Lampropoulou-Adamidou, K. et al. Chondroprotective effect of high-dose zoledronic acid: an experimental study in a rabbit model of osteoarthritis. J. Orthop. Res. 32, 1646–1651 (2014).
pubmed: 25125266
Mohan, G. et al. Pre-emptive, early, and delayed alendronate treatment in a rat model of knee osteoarthritis: effect on subchondral trabecular bone microarchitecture and cartilage degradation of the tibia, bone/cartilage turnover, and joint discomfort. Osteoarthritis Cartilage 21, 1595–1604 (2013).
pubmed: 23827368
Siebelt, M. et al. Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression. Bone 66, 163–170 (2014).
pubmed: 24933343
Funck-Brentano, T. et al. Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism. PLoS One 7, e33543 (2012).
pubmed: 22432033
pmcid: 3303845
Kadri, A. et al. Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling. Ann. Rheum. Dis. 69, 1533–1538 (2010).
pubmed: 20525838
Zhu, S. et al. Alendronate protects against articular cartilage erosion by inhibiting subchondral bone loss in ovariectomized rats. Bone 53, 340–349 (2013).
pubmed: 23291609
Roman-Blas, J. A. et al. Phenotype may obtain major benefit from bone-acting agents. Semin. Arthritis Rheum. 43, 421–428 (2014).
pubmed: 24016748
Vaysbrot, E. E., Osani, M. C., Musetti, M. C., McAlindon, T. E. & Bannuru, R. R. Are bisphosphonates efficacious in knee osteoarthritis? A meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 26, 154–164 (2018).
pubmed: 29222056
Damman, W. et al. Bone marrow lesions and synovitis on MRI associate with radiographic progression after 2 years in hand osteoarthritis. Ann. Rheum. Dis. 76, 214–217 (2017).
pubmed: 27323771
Felson, D. T. et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann. Intern. Med. 139, 330–336 (2003).
pubmed: 12965941
Haugen, I. K. et al. MRI findings predict radiographic progression and development of erosions in hand osteoarthritis. Ann. Rheum. Dis. 75, 117–123 (2016).
pubmed: 25204463
Yusuf, E., Kortekaas, M. C., Watt, I., Huizinga, T. W. & Kloppenburg, M. Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review. Ann. Rheum. Dis. 70, 60–67 (2011).
pubmed: 20829200
Cai, G. et al. Effect of intravenous zoledronic acid on tibiofemoral cartilage volume among patients with knee osteoarthritis with bone marrow lesions: a randomized clinical trial. JAMA 323, 1456–1466 (2020).
pubmed: 32315057
pmcid: 7175085
Deveza, L. A. et al. Efficacy of bisphosphonates in specific knee osteoarthritis subpopulations: protocol for an OA Trial Bank systematic review and individual patient data meta-analysis. BMJ Open 8, e023889 (2018).
pubmed: 30573485
pmcid: 6303587
Laslett, L. L., Kingsbury, S. R., Hensor, E. M., Bowes, M. A. & Conaghan, P. G. Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative. Ann. Rheum. Dis. 73, 824–830 (2014).
pubmed: 23585518
Neogi, T., Li, S., Peloquin, C., Misra, D. & Zhang, Y. Effect of bisphosphonates on knee replacement surgery. Ann. Rheum. Dis. 77, 92–97 (2018).
pubmed: 28988204
Haj-Mirzaian, A. et al. Bisphosphonates intake and its association with changes of periarticular bone area and three-dimensional shape: data from the Osteoarthritis Initiative (OAI). Osteoarthritis Cartilage 26, 564–568 (2018).
pubmed: 29330102
Heidari, B. & Babaei, M. Therapeutic and preventive potential of vitamin D supplementation in knee osteoarthritis. ACR Open Rheumatol. 1, 318–326 (2019).
pubmed: 31777808
pmcid: 6857993
Arden, N. K. et al. The effect of vitamin D supplementation on knee osteoarthritis, the VIDEO study: a randomised controlled trial. Osteoarthritis Cartilage 24, 1858–1866 (2016).
pubmed: 27264058
pmcid: 5045720
Jin, X. et al. Effect of Vitamin D supplementation on tibial cartilage volume and knee pain among patients with symptomatic knee osteoarthritis: a randomized clinical trial. JAMA 315, 1005–1013 (2016).
pubmed: 26954409
McAlindon, T. et al. Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial. JAMA 309, 155–162 (2013).
pubmed: 23299607
pmcid: 3984919
Perry, T. A. et al. Effect of Vitamin D supplementation on synovial tissue volume and subchondral bone marrow lesion volume in symptomatic knee osteoarthritis. BMC Musculoskelet. Disord. 20, 76 (2019).
pubmed: 30764805
pmcid: 6376763
Zheng, S. et al. Maintaining vitamin D sufficiency is associated with improved structural and symptomatic outcomes in knee osteoarthritis. Am. J. Med. 130, 1211–1218 (2017).
pubmed: 28549923
Sanghi, D. et al. Does vitamin D improve osteoarthritis of the knee: a randomized controlled pilot trial. Clin. Orthop. Relat. Res. 471, 3556–3562 (2013).
pubmed: 23904246
pmcid: 3792285
Jin, X. et al. Effect of vitamin D supplementation on pain and physical function in patients with knee osteoarthritis (OA): an OA Trial Bank protocol for a systematic review and individual patient data (IPD) meta-analysis. BMJ Open 10, e035302 (2020).
pubmed: 32332006
pmcid: 7204938
Bossard, M. J. et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J. Biol. Chem. 271, 12517–12524 (1996).
pubmed: 8647860
Drake, F. H. et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 271, 12511–12516 (1996).
pubmed: 8647859
Hou, W. S. et al. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum. 46, 663–674 (2002).
pubmed: 11920402
Konttinen, Y. T. et al. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum. 46, 953–960 (2002).
pubmed: 11953972
Dejica, V. M. et al. Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage. Am. J. Pathol. 173, 161–169 (2008).
pubmed: 18511517
pmcid: 2438294
Mort, J. S. et al. Early cathepsin K degradation of type II collagen in vitro and in vivo in articular cartilage. Osteoarthritis Cartilage 24, 1461–1469 (2016).
pubmed: 27049030
Hayami, T., Zhuo, Y., Wesolowski, G. A., Pickarski, M. & Duong, L. T. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone 50, 1250–1259 (2012).
pubmed: 22484689
Kozawa, E. et al. Osteoarthritic change is delayed in a Ctsk-knockout mouse model of osteoarthritis. Arthritis Rheum. 64, 454–464 (2012).
pubmed: 21968827
Soki, F. N. et al. Articular cartilage protection in Ctsk
pubmed: 29781506
McClung, M. R. et al. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol. 7, 899–911 (2019).
pubmed: 31676222
Lindstrom, E. et al. The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis. J. Transl. Med. 16, 56 (2018).
pubmed: 29523155
pmcid: 5845353
Robinson, W. H. et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol. 12, 580–592 (2016).
pubmed: 27539668
pmcid: 5500215
Hill, C. L. et al. Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritis. Ann. Rheum. Dis. 66, 1599–1603 (2007).
pubmed: 17491096
pmcid: 2095318
Stoppiello, L. A. et al. Structural associations of symptomatic knee osteoarthritis. Arthritis Rheumatol. 66, 3018–3027 (2014).
pubmed: 25049144
pmcid: 4309484
Sarmanova, A., Hall, M., Moses, J., Doherty, M. & Zhang, W. Synovial changes detected by ultrasound in people with knee osteoarthritis - a meta-analysis of observational studies. Osteoarthritis Cartilage 24, 1376–1383 (2016).
pubmed: 26973325
pmcid: 4967443
Atukorala, I. et al. Synovitis in knee osteoarthritis: a precursor of disease? Ann. Rheum. Dis. 75, 390–395 (2016).
pubmed: 25488799
Felson, D. T. et al. Synovitis and the risk of knee osteoarthritis: the MOST Study. Osteoarthritis Cartilage 24, 458–464 (2016).
pubmed: 26432512
Roemer, F. W. et al. What comes first? Multitissue involvement leading to radiographic osteoarthritis: magnetic resonance imaging-based trajectory analysis over four years in the Osteoarthritis Initiative. Arthritis Rheumatol. 67, 2085–2096 (2015).
pubmed: 25940308
pmcid: 4519416
Wang, X. et al. Quantitative assessment of knee effusion-synovitis in older adults: association with knee structural abnormalities. Arthritis Rheumatol. 68, 837–844 (2016).
pubmed: 26636246
Conaghan, P. G. et al. Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann. Rheum. Dis. 69, 644–647 (2010).
pubmed: 19433410
Wenham, C. Y. et al. A randomized, double-blind, placebo-controlled trial of low-dose oral prednisolone for treating painful hand osteoarthritis. Rheumatology 51, 2286–2294 (2012).
pubmed: 22956551
Kroon, F. P. B. et al. Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial. Lancet 394, 1993–2001 (2019).
pubmed: 31727410
Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H. & Foster, C. S. Long-term side effects of glucocorticoids. Expert Opin. Drug Saf. 15, 457–465 (2016).
pubmed: 26789102
Conaghan, P. G. et al. Effects of a single intra-articular injection of a microsphere formulation of triamcinolone acetonide on knee osteoarthritis pain: a double-blinded, randomized, placebo-controlled, multinational study. J. Bone Jt. Surg. Am. 100, 666–677 (2018).
Conaghan, P. G. et al. Brief report: a phase IIb trial of a novel extended-release microsphere formulation of triamcinolone acetonide for intraarticular injection in knee osteoarthritis. Arthritis Rheumatol. 70, 204–211 (2018).
pubmed: 29088579
Kraus, V. B. et al. Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). Osteoarthritis Cartilage 26, 34–42 (2018).
pubmed: 29024802
Russell, S. J. et al. Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study. Rheumatology 57, 2235–2241 (2018).
pubmed: 30203101
Hartmann, K. et al. Molecular actions of glucocorticoids in cartilage and bone during health, disease, and steroid therapy. Physiol. Rev. 96, 409–447 (2016).
pubmed: 26842265
Kompel, A. J. et al. Intra-articular corticosteroid injections in the hip and knee: perhaps not as safe as we thought? Radiology 293, 656–663 (2019).
pubmed: 31617798
Leung, Y. Y., Huebner, J. L., Haaland, B., Wong, S. B. S. & Kraus, V. B. Synovial fluid pro-inflammatory profile differs according to the characteristics of knee pain. Osteoarthritis Cartilage 25, 1420–1427 (2017).
pubmed: 28433814
Sohn, D. H. et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4. Arthritis Res. Ther. 14, R7 (2012).
pubmed: 22225630
pmcid: 3392793
Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J. P. & Fahmi, H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 7, 33–42 (2011).
pubmed: 21119608
Chevalier, X. et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 61, 344–352 (2009).
pubmed: 19248129
Cohen, S. B. et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res. Ther. 13, R125 (2011).
pubmed: 21801403
pmcid: 3239365
Kloppenburg, M. et al. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Ann. Rheum. Dis. 78, 413–420 (2019).
pubmed: 30552176
Fleischmann, R. M. et al. A phase II trial of lutikizumab, an anti-interleukin-1α/β dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis. Arthritis Rheumatol. 71, 1056–1069 (2019).
pubmed: 30653843
van Dalen, S. C. et al. Interleukin-1 is not involved in synovial inflammation and cartilage destruction in collagenase-induced osteoarthritis. Osteoarthritis Cartilage 25, 385–396 (2017).
pubmed: 27654963
Nasi, S., Ea, H. K., So, A. & Busso, N. Revisiting the role of interleukin-1 pathway in osteoarthritis: interleukin-1α and -1β, and NLRP3 inflammasome are not involved in the pathological features of the murine menisectomy model of osteoarthritis. Front. Pharmacol. 8, 282 (2017).
pubmed: 28659793
pmcid: 5468399
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
Schieker, M. et al. Effects of interleukin-1β inhibition on incident hip and knee replacement: exploratory analyses from a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 173, 509–515 (2020).
pubmed: 32744862
Wittoek, R. et al. Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis: a proof-of-concept study. Ann. Rheum. Dis. 77, 310–311 (2018).
pubmed: 27932347
Loef, M. et al. TNF inhibitor treatment is associated with a lower risk of hand osteoarthritis progression in rheumatoid arthritis patients after 10 years. Rheumatology 57, 1917–1924 (2018).
pubmed: 29471377
Aitken, D. et al. A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis — the HUMOR trial. Osteoarthritis Cartilage 26, 880–887 (2018).
pubmed: 29499287
Chevalier, X. et al. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 74, 1697–1705 (2015).
pubmed: 24817417
Verbruggen, G., Wittoek, R., Vander Cruyssen, B. & Elewaut, D. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann. Rheum. Dis. 71, 891–898 (2012).
pubmed: 22128078
Kloppenburg, M. et al. Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 77, 1757–1764 (2018).
pubmed: 30282670
Leung, Y. Y. et al. Colchicine lack of effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial. Osteoarthritis Cartilage 26, 631–640 (2018).
pubmed: 29426008
Larsson, S., Englund, M., Struglics, A. & Lohmander, L. S. Interleukin-6 and tumor necrosis factor alpha in synovial fluid are associated with progression of radiographic knee osteoarthritis in subjects with previous meniscectomy. Osteoarthritis Cartilage 23, 1906–1914 (2015).
pubmed: 26521736
Goekoop, R. J. et al. Low innate production of interleukin-1β and interleukin-6 is associated with the absence of osteoarthritis in old age. Osteoarthritis Cartilage 18, 942–947 (2010).
pubmed: 20417290
Livshits, G. et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: The Chingford Study. Arthritis Rheum. 60, 2037–2045 (2009).
pubmed: 19565477
pmcid: 2841820
Stannus, O. et al. Circulating levels of IL-6 and TNF-α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage 18, 1441–1447 (2010).
pubmed: 20816981
Latourte, A. et al. Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis. Ann. Rheum. Dis. 76, 748–755 (2017).
pubmed: 27789465
Ryu, J. H. et al. Interleukin-6 plays an essential role in hypoxia-inducible factor 2alpha-induced experimental osteoarthritic cartilage destruction in mice. Arthritis Rheum. 63, 2732–2743 (2011).
pubmed: 21590680
Cook, A. D. et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis Res. Ther. 14, R199 (2012).
pubmed: 22995428
pmcid: 3580511
Schett, G. et al. A phase IIa study of anti-GM-CSF antibody GSK3196165 in subjects with inflammatory hand osteoarthritis [abstract]. Arthritis Rheumatol. 70 (2018).
Achuthan, A. et al. Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation. J. Clin. Invest. 126, 3453–3466 (2016).
pubmed: 27525438
pmcid: 5004969
Li, T. et al. TGF-beta type 2 receptor-mediated modulation of the IL-36 family can be therapeutically targeted in osteoarthritis. Sci. Transl. Med. 11, eaan2585 (2019).
pubmed: 31068441
pmcid: 7102613
Evans, C. H., Ghivizzani, S. C. & Robbins, P. D. Gene delivery to joints by intra-articular injection. Hum. Gene Ther. 29, 2–14 (2018).
pubmed: 29160173
pmcid: 5773261
Nusse, R. & Clevers, H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985–999 (2017).
pubmed: 28575679
pmcid: 28575679
Lories, R. J., Corr, M. & Lane, N. E. To Wnt or not to Wnt: the bone and joint health dilemma. Nat. Rev. Rheumatol. 9, 328–339 (2013).
pubmed: 23459013
pmcid: 4830431
Lambert, C. et al. Gene expression pattern of cells from inflamed and normal areas of osteoarthritis synovial membrane. Arthritis Rheumatol. 66, 960–968 (2014).
pubmed: 24757147
pmcid: 4033569
Nakamura, Y., Nawata, M. & Wakitani, S. Expression profiles and functional analyses of Wnt-related genes in human joint disorders. Am. J. Pathol. 167, 97–105 (2005).
pubmed: 15972956
pmcid: 1603448
Lories, R. J. et al. Articular cartilage and biomechanical properties of the long bones in Frzb-knockout mice. Arthritis Rheum. 56, 4095–4103 (2007).
pubmed: 18050203
Monteagudo, S. et al. DOT1L safeguards cartilage homeostasis and protects against osteoarthritis. Nat. Commun. 8, 15889 (2017).
pubmed: 28627522
pmcid: 5481839
Thysen, S., Luyten, F. P. & Lories, R. J. Loss of Frzb and Sfrp1 differentially affects joint homeostasis in instability-induced osteoarthritis. Osteoarthritis Cartilage 23, 275–279 (2015).
pubmed: 25450854
Zhu, M. et al. Inhibition of beta-catenin signaling in articular chondrocytes results in articular cartilage destruction. Arthritis Rheum. 58, 2053–2064 (2008).
pubmed: 18576323
pmcid: 2667964
Zhu, M. et al. Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J. Bone Miner. Res. 24, 12–21 (2009).
pubmed: 18767925
van den Bosch, M. H. et al. Induction of canonical Wnt Signaling by synovial overexpression of selected wnts leads to protease activity and early osteoarthritis-like cartilage damage. Am. J. Pathol. 185, 1970–1980 (2015).
pubmed: 25976248
Nalesso, G. et al. WNT16 antagonises excessive canonical WNT activation and protects cartilage in osteoarthritis. Ann. Rheum. Dis. 76, 218–226 (2017).
pubmed: 27147711
Lietman, C. et al. Inhibition of Wnt/β-catenin signaling ameliorates osteoarthritis in a murine model of experimental osteoarthritis. JCI Insight 3, e96308 (2018).
pmcid: 5821202
Deshmukh, V. et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 26, 18–27 (2018).
pubmed: 28888902
Deshmukh, V. et al. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. Osteoarthritis Cartilage 27, 1347–1360 (2019).
pubmed: 31132406
Yazici, Y. et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis Cartilage 25, 1598–1606 (2017).
pubmed: 28711582
Yazici, Y. et al. Results from a 52 week randomized, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular, Wnt pathway inhibitor (SM04690) for the treatment of knee osteoarthritis [abstract]. Arthritis Rheumatol. 69 (2017).
Yazici, Y. et al. Efficacy and safety from a phase 2b trial of SM04690, a novel, intra-articular, Wnt pathway inhibitor for the treatment of osteoarthritis of the knee [abstract]. Arthritis Rheumatol. 70 (2018).
Gossec, L. et al. The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement. Osteoarthritis Cartilage 19, 147–154 (2011).
pubmed: 21044689
Malfait, A. M. & Schnitzer, T. J. Towards a mechanism-based approach to pain management in osteoarthritis. Nat. Rev. Rheumatol. 9, 654–664 (2013).
pubmed: 24045707
pmcid: 4151882
Obeidat, A. M., Miller, R. E., Miller, R. J. & Malfait, A. M. The nociceptive innervation of the normal and osteoarthritic mouse knee. Osteoarthritis Cartilage 27, 1669–1679 (2019).
pubmed: 31351964
pmcid: 7020657
Neogi, T. et al. Association of joint inflammation with pain sensitization in knee osteoarthritis: the multicenter osteoarthritis study. Arthritis Rheumatol. 68, 654–661 (2016).
pubmed: 26554395
pmcid: 4827020
Brenn, D., Richter, F. & Schaible, H. G. Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: an inflammatory mechanism of joint pain. Arthritis Rheum. 56, 351–359 (2007).
pubmed: 17195239
Richter, F. et al. Tumor necrosis factor causes persistent sensitization of joint nociceptors to mechanical stimuli in rats. Arthritis Rheum. 62, 3806–3814 (2010).
pubmed: 20722011
Neogi, T. et al. Sensitivity and sensitisation in relation to pain severity in knee osteoarthritis: trait or state? Ann. Rheum. Dis. 74, 682–688 (2015).
pubmed: 24351516
Steen Pettersen, P. et al. Peripheral and central sensitization of pain in individuals with hand osteoarthritis and associations with self-reported pain severity. Arthritis Rheumatol. 71, 1070–1077 (2019).
pubmed: 30741501
Stefanik, J. J. et al. Changes in pain sensitization after bariatric surgery. Arthritis Care Res. 70, 1525–1528 (2018).
Miller, R. E. et al. Chemogenetic inhibition of pain neurons in a mouse model of osteoarthritis. Arthritis Rheumatol. 69, 1429–1439 (2017).
pubmed: 28380690
pmcid: 5501168
Chen, L. et al. Efficacy and tolerability of duloxetine in patients with knee osteoarthritis: a meta-analysis of randomised controlled trials. Intern. Med. J. 49, 1514–1523 (2019).
pubmed: 30993832
Osani, M. C. & Bannuru, R. R. Efficacy and safety of duloxetine in osteoarthritis: a systematic review and meta-analysis. Korean J. Intern. Med. 34, 966–973 (2019).
pubmed: 30871298
pmcid: 6718752
Weng, C., Xu, J., Wang, Q., Lu, W. & Liu, Z. Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain: a systematic review and meta-analysis. Osteoarthritis Cartilage 28, 721–734 (2020).
pubmed: 32169731
Woolf, C. J., Safieh-Garabedian, B., Ma, Q. P., Crilly, P. & Winter, J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 62, 327–331 (1994).
pubmed: 7530342
Mantyh, P. W., Koltzenburg, M., Mendell, L. M., Tive, L. & Shelton, D. L. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology 115, 189–204 (2011).
pubmed: 21602663
pmcid: 3121917
Tominaga, M. et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21, 531–543 (1998).
pubmed: 9768840
Seidel, M. F., Herguijuela, M., Forkert, R. & Otten, U. Nerve growth factor in rheumatic diseases. Semin. Arthritis Rheum. 40, 109–126 (2010).
pubmed: 19481238
Miller, R. E., Block, J. A. & Malfait, A. M. Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models? Curr. Opin. Rheumatol. 29, 110–118 (2017).
pubmed: 27672741
pmcid: 5436144
von Loga, I. S. et al. Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis. Ann. Rheum. Dis. 78, 672–675 (2019).
Lane, N. E. et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med. 363, 1521–1531 (2010).
pubmed: 20942668
pmcid: 6896791
Tive, L. et al. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J. Pain Res. 12, 975–995 (2019).
pubmed: 30936738
pmcid: 6430070
Roemer, F. W. & Guermazi, A. Imaging atlas for eligibility and on-study safety of potential joint adverse events in anti-NGF studies. Osteoarthritis Cartilage 23, S1–S2 (2015).
pubmed: 25527215
Hochberg, M. C. et al. When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol. 68, 382–391 (2016).
pubmed: 26554876
Belanger, P. et al. From the cover: evaluation of the effects of tanezumab, a monoclonal antibody against nerve growth factor, on the sympathetic nervous system in adult cynomolgus monkeys (Macaca fascicularis): a stereologic, histomorphologic, and cardiofunctional assessment. Toxicol. Sci. 158, 319–333 (2017).
pubmed: 28525647
pmcid: 5837719
Schnitzer, T. J. et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. JAMA 322, 37–48 (2019).
pubmed: 31265100
pmcid: 6613301
Berenbaum, F. et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann. Rheum. Dis. 79, 800–810 (2020).
pubmed: 32234715
pmcid: 7286052
Hochberg, M. C. et al. Subcutaneous tanezumab versus NSAID for the treatment of osteoarthritis: joint safety events in a randomized, double-blind, active-controlled, 80-week, phase-3 study [abstract]. Arthritis Rheumatol. 71 (2019).
Dakin, P. et al. The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: a phase IIb/III double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol. 71, 1824–1834 (2019).
pubmed: 31207169
pmcid: 6900077
Huskisson, E. C., Berry, H., Gishen, P., Jubb, R. W. & Whitehead, J. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal investigation of nonsteroidal antiinflammatory drugs in knee osteoarthritis. J. Rheumatol. 22, 1941–1946 (1995).
pubmed: 8991995
Rashad, S. et al. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 2, 519–522 (1989).
pubmed: 2570233
Reijman, M. et al. Is there an association between the use of different types of nonsteroidal antiinflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam Study. Arthritis Rheum. 52, 3137–3142 (2005).
pubmed: 16200593
Ding, C., Cicuttini, F. & Jones, G. Do NSAIDs affect longitudinal changes in knee cartilage volume and knee cartilage defects in older adults? Am. J. Med. 122, 836–842 (2009).
pubmed: 19699379
Nakata, K. et al. Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review. Osteoarthritis Cartilage 26, 1263–1273 (2018).
pubmed: 29890262
LaBranche, T. P. et al. Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model. Ann. Rheum. Dis. 76, 295–302 (2017).
pubmed: 27381034
Li, Z. et al. Fracture repair requires TrkA signaling by skeletal sensory nerves. J. Clin. Invest. 129, 5137–5150 (2019).
pubmed: 31638597
pmcid: 6877307
Tomlinson, R. E. et al. NGF-TrkA signaling in sensory nerves is required for skeletal adaptation to mechanical loads in mice. Proc. Natl Acad. Sci. USA 114, E3632–E3641 (2017).
pubmed: 28416686
Watt, F. E. et al. Tropomyosin-related kinase A (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial. Osteoarthritis Cartilage 27, 1590–1598 (2019).
pubmed: 31356878
Krupka, E., Jiang, G. L. & Jan, C. Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study. Osteoarthritis Cartilage 27, 1599–1607 (2019).
pubmed: 31351965
Simone, D. A., Nolano, M., Johnson, T., Wendelschafer-Crabb, G. & Kennedy, W. R. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J. Neurosci. 18, 8947–8959 (1998).
pubmed: 9787000
pmcid: 6793545
Stevens, R. M. et al. Randomized, double-blind, placebo-controlled trial of intraarticular trans-capsaicin for pain associated with osteoarthritis of the knee. Arthritis Rheumatol. 71, 1524–1533 (2019).
pubmed: 30888737
pmcid: 6772016
Arsenault, P. et al. NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain. Pain Rep. 3, e696 (2018).
pubmed: 30706039
pmcid: 6344137
Carlesso, L. C. & Neogi, T. Identifying pain susceptibility phenotypes in knee osteoarthritis. Clin. Exp. Rheumatol. 37, 96–99 (2019).
pubmed: 31621573
pmcid: 6946180
Deveza, L. A., Nelson, A. E. & Loeser, R. F. Phenotypes of osteoarthritis: current state and future implications. Clin. Exp. Rheumatol. 37, 64–72 (2019).
pubmed: 31621574
pmcid: 6936212